|
May 9
|
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Numbers Came Up A Little Short’
|
|
May 9
|
1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
|
|
May 8
|
Regeneron Pharmaceuticals, Inc. (REGN): Among the Cheap ESG Stocks to Buy According to Hedge Funds
|
|
May 7
|
Regeneron Pharmaceuticals (REGN): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential
|
|
Apr 22
|
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
|
|
Apr 22
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership
|
|
Apr 22
|
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom
|
|
Apr 22
|
Regeneron partners with Fujifilm to broaden manufacturing capacity
|
|
Apr 22
|
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 22
|
Drug Companies Step Up 'Make in America' Plans to Counter Tariffs
|
|
Apr 22
|
Regeneron to invest over $3 billion to boost US manufacturing
|
|
Apr 22
|
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
|
|
Apr 21
|
Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer
|
|
Apr 21
|
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
|
|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 17
|
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
|